American society of clinical oncology 2013 top five list in oncology

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4362-4370

  Schnipper, Lowell E ^a   Lyman, Gary H ^b   Blayney, Douglas W ^d   Hoverman, J Russell ^e   Raghavan, Derek ^c   Wollins, Dana S ^f   Schilsky, Richard L ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e TEXAS ONCOLOGY   (United States)

^f AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PREVENTION; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL SOCIETY; ONCOLOGY; PATIENT CARE; PRIORITY JOURNAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; MOLECULARLY TARGETED THERAPY; MULTIMODAL IMAGING; PATIENT SELECTION; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; STANDARD; UNITED STATES; UNNECESSARY PROCEDURE; STANDARDS;

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GUIDELINE ADHERENCE; HUMANS; INDIVIDUALIZED MEDICINE; KALLIKREINS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; MULTIMODAL IMAGING; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 84892900404     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.3943     Document Type: Article

References (55)

1. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
2. Centers for Medicare and Medicaid Services: National health expenditures projections 2011-2021. http:// www.cms.gov/Research-Statistics-data-and-Systems/ Statistics-Trends-and-Reports/NationalHealth ExpendData/Downloads/Proj2011PDF. pdf
3. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715- 1724, 2012
4. Roehrig C, Turner A, Hughes-Cromwick P, et al: When the cost curve bent: Pre-recession moderation in health care spending. N Engl J Med 367: 590-593, 2012
5. Kaufman K: Bending the cost curve: More than meets the eye? http://healthaffairs.org/blog/2012/04/13/ bending-the-health-care-cost-curve- more-than-meetsthe- eye/?goback-gde-1878748-member-107737725
6. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011
7. Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
8. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
9. Yu Z, Liu W, Wang L, et al: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99-102, 2009
10. Cardoso F, Costa A, Norton L, et al: 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1). Breast 21:242-252, 2012
11. Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372, 2009
12. National Comprehensive Cancer Network: Clinical practice guidelines in oncology - Breast cancer version 1.2013, section BINV-O. http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf
13. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
14. Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
15. Howell A, Robertson JF, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
16. Lutz S, Berk L, Chang E, et al: Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965-976, 2011
17. Verboom P, van Tinterer H, Hoekstra OS, et al: Cost-effectiveness of FDG-PET in staging nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 30:1444-1449, 2003 (Pubitemid 37356109)
18. Gambhir SS, Shepherd JE, Shah BD, et al: Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 16:2113-2125, 1998 (Pubitemid 28265048)
19. Centers for Medicare and Medicaid Services: Decisionmemofor positron emission tomography (FDG) for solid tumors (CAG-00181R4). http://www.cms.gov/ medicare-coverage-database/details/nca-decisionmemo.aspx?NCAId-26
20. Cancer Care Ontario: PET imaging in Ontario. http://www.cancercare.on.ca/ ocs/clinicalprogs/imaging/ pet
21. Labianca R, Norlinger B Becotta GD, et al: Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and followup. Ann Oncol 21:v70-v77, 2010 (suppl 5)
22. Cheah CY, Hofman MS, Dickinson M, et al: Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109:312-317, 2013
23. Zinzani P, Tani M, Trisolini R, et al: Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92:771-777, 2007 (Pubitemid 350155302)
24. Evangelista L, Baretta, Vinante L, et al: Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 38:293-301, 2011
25. Sobhani I, Tiret E, Lebtahi R, et al: Early detection of recurrence by 18 FDG-PET/CT in the follow-up of patients with colorectal cancer. Br J Cancer 98:875-880, 2008 (Pubitemid 351341613)
26. Thompson CA, Maurer MJ, Ghesquieres H, et al: Utility of post-therapy surveillance scans in DCBCL. J Clin Oncol 31:519s, 2013 (suppl; abstr 8504)
27. Pingali SR, Sewell S, Havlat L, et al: Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 31:519s, 2013 (suppl; abstr 8505)
28. Raghavan D: PSA: Please stop agonizing (over prostate-specific antigen interpretation). Mayo Clin Proc 88:1-3, 2013
29. Kuriyama M, Wang MC, Lee CI, et al: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874-3876, 1981 (Pubitemid 11011166)
30. Loeb S, Carter HB, Catalona WJ, et al: Baseline prostate-specific antigen testing at a young age. Eur Urol 61:1-7, 2012
31. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320- 1328, 2009
32. Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
33. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
34. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostatecancer screening trial. N Engl J Med 360:1310-1319, 2009
35. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762-771, 2011
36. Moyer VA: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134, 2012
37. Qaseem A, Barry MJ, Denberg TD, et al: Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 158:761-769, 2013
38. Carter HB, Albertson PC, Barry MJ, et al: Early detection of prostate cancer: AUA Guideline. J Urol 190:419-426, 2013
39. Basch E, Oliver TK, Vickers A, et al: Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 30:3020-3025, 2012
40. Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-761, 1985 (Pubitemid 15022931)
41. Druker B, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
42. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
43. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
44. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
45. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694- 1703, 2012
46. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lunch cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
47. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
48. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
49. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)
50. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007 (Pubitemid 46797944)
51. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757- 1765, 2008
52. Allegra C, Jessup J, Somerfield M, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
53. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
54. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
55. Jimeno A, Messersmith WA, Hirsch FR, et al: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J 15:110- 113, 2009